Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether his Department plans to establish an independent inquiry into the historic prescribing of Diethylstilbestrol.

The issue of diethylstilbesterol (DES) and vaginal carcinoma in the daughters of women who took DES during pregnancy was reviewed by the Committee on Safety of Medicines (CSM) in the early 1970s. In 1973, the CSM wrote to all doctors to inform them of the results of a study into the topic from the United States, and the absence of identified cases in the United Kingdom.

The work of the committee predates the existence of the Medicines and Healthcare products Regulatory Agency (MHRA), when medicines vigilance was only in its infancy and there were no electronic records and no systematic monitoring of prescriptions.

There has been a step change in reporting and record keeping since this time, and today's regulatory frameworks are significantly different, with much stricter post-authorisation monitoring allowing for earlier identification and action on emerging safety issues. The MHRA regulates medicines supplied in the UK. Its activity spans the whole of a medicine’s lifecycle. The MHRA keeps the safety of all medicines under continual review.

Government advice currently is that routine cervical screening is appropriate for those who believe they were exposed to DES in utero. Further information is available at the following link:

https://www.gov.uk/government/publications/cervical-screening-programme-and-colposcopy-management/5-screening-and-management-of-immunosuppressed-individuals

Participation in the National Breast Screening Programme is also recommended. Pregnant women who know that they were exposed in utero to DES should inform their obstetrician and be aware of the increased risks of ectopic pregnancy and preterm labour.

The Department does not have any plans to establish a public inquiry into the historic prescribing of DES.